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Objective: A retrospective review of long-term treatment outcomes for patients diagnosed with inter-
stitial cystitis/painful bladder syndrome (IC/PBS) over a 10-year period.
Materials and Methods: Patients who were diagnosed with IC/PBS based on cystoscopic hydrodistention
from 2001 to 2010 and thereafter received regular follow-up treatments were enrolled in this study.
Clinical informationwas collected via a retrospective chart review. The following aspects were evaluated:
treatment modalities and outcomes; symptom manifestation before and after treatments; and patients’
perception on treatment effectiveness. The O’LearyeSant Interstitial Cystitis Symptom Index (ICSI) and
Interstitial Cystitis Problem Index (ICPI), and the Global Response Assessment Questionnaire were used
as evaluation tools.
Results: A total of 54 patients with adequate clinical information were included for analysis in this study.
The mean age was 38.11  12.71 years and the female-to-male ratio was 3.15:1. The average follow-up
duration was 30.61  25.54 months. All patients had bladder or pelvic pain. Pretreatment urinary fre-
quency and nocturia were 13.43  5.09 times per day and 3.74  2.18 times per night, respectively.
Functional bladder capacity recorded from urinary diary was 228.1  116.5 mL. Under anesthesia, bladder
capacity at the start of a 10-minute therapeutic hydrodistention was 422.0  197.5 mL, which increased
to 542.9  220.1 mL at the end of hydrodistention. No major complications were reported during and
after the procedure. Additional treatments including oral medications and bladder instillation therapies
were instituted in 98.1% of patients. Compared with pretreatment condition, the O’LearyeSant ICSI and
ICPI were decreased by 24% and 15.5%, respectively, after treatments. The subjective improvement rate,
which was evaluated by the Global Response Assessment Questionnaire, was 81.6%.
Conclusion: Long-term continual treatments for IC/PBS are appreciated by most patients even though
combinations of modalities are required and the improvements in symptoms and problems are only
moderate.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Interstitial cystitis/painful bladder syndrome (IC/PBS) is a dis-
ease of bladder pain characterized by urgency to urinate, frequent
urination, nocturia, and dysuria. The disease causes serious
impairment to quality of life in the affected patients. Clinically, the
patients present with a wide spectrum of symptoms, physical ex-
amination ﬁndings, and clinical test responses.1 According to the
diagnostic inclusion and exclusion criteria established by the Na-
tional Institute of Diabetes, Digestive and Kidney Diseases (NIDDK),
bladder hydrodistention is a recommended test for the diagnosis oftional Cheng Kung University
ng).
ciation. Published by Elsevier TaiwIC/PBS. Besides, a clinical guideline for IC/PBS developed by a group
of East Asian urologists indicates that performing cystoscopy with
hydrodistention is crucial and should be recommended for deﬁni-
tive diagnosis.2 In contrast, according to the latest American Uro-
logical Association (AUA) guideline for IC/PBS, cystoscopy is not
necessary for making the diagnosis in uncomplicated pre-
sentations. However, the procedure is still listed as a third-line
treatment option for IC/PBS.3
Etiologies of IC/PBS are multifactorial and complicated. It has
been postulated that interactions among urothelial, nervous,
immunological, and endocrinological factors form a vicious cycle,
provocating and maintaining inﬂammatory reactions in the
bladder.2 In accordance, a myriad of therapeutic modalities are
developed based on the pathophysiological processes. According to
the AUA guideline, the following six lines of treatment arean LLC. Open access under CC BY-NC-ND license.
Table 1
Basic information of patients and voiding diary before treatment (n ¼ 54).
Mean Median SD Range
Age (y) 38.11 35.50 12.71 17e72
Follow-up duration (mo) 30.61 26.50 25.54 3e122
Functional bladder capacity (mL) 228.1 220.0 116.5 30e500
Daytime frequency 13.43 12.0 5.09 6e40
Nocturia 3.74 3.0 2.18 1e10
mo ¼ months; y ¼ years.
Table 2
Additional treatment modalities after hydrodistention (n ¼ 54).
Patients Percentage
Treatments
Pentosan polysulfate 44 81.5%
Heparin 32 59.3%
Hyaluronic acid 25 46.3%
Number of treatments
0 1 1.9%
1 20 37.0%
2 18 33.3%
3 15 27.8%
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agement, oral medication (amitriptyline, cimetidine, hydroxyzine,
or pentosan polysulfate), bladder instillation therapy (dimethyl
sulfoxide, heparin, lidocaine); (3) cystoscopy/hydrodistention, ul-
cer fulguration; (4) neurostimulation; (5) cyclosporine, botulinum
toxin A; and (6) major surgery (cystoplasty, diversion).3
Baseline and regular symptom severity assessments are essential
to monitor clinical progress in patients with IC/PBS. Questionnaires
for the evaluation of IC/PBS symptoms and patient well-being are
widely used. Commonly used assessment tools are Global Response
Index; O’LearyeSant Interstitial Cystitis Symptom Index (ICSI), and
Interstitial Cystitis Problem Index (ICPI) as well as Pain, Urgency,
Frequency Symptom Scale. Kushner et al demonstrated that the
Pain, Urgency, Frequency Symptom Scale and the O’LearyeSant ICSI
and ICPI were useful as both a screening tool and a treatment
evaluation tool for IC/PBS.3
This study was aimed to report our experience with IC/PBS pa-
tients who had been diagnosed by cystoscopic hydrodistention and
received long-term regular treatments. The O’LearyeSant ICSI and
ICPI, and the Global Response Assessment Questionnaire were used
as evaluation tools.
2. Materials and methods
From January 2001 to March 2011, patients whowere diagnosed
with IC/PBS after hydrodistention and received regular follow-up
treatments in the National Cheng Kung University Hospital
(NCKUH) were retrospectively enrolled in this study. The diagnosis
of IC/PBS was made according to the NIDDK criteria.4 The cysto-
scopic criteria for diagnosis included presence of Hunner’s ulcer or
diffuse glomerulations over three quadrants of the bladder after
hydrodistention. Under spinal or general anesthesia, diagnostic
hydrodistention was performed under a hydrostatic pressure of 80
cmH2O for 2 minutes. Therapeutic hydrodistention was then per-
formed under the same pressure for another 10 minutes if the
cystoscopic ﬁndings were compatible with IC/PBS. Besides hydro-
distention, combination treatments with oral analgesics, pentosan
polysulfate, and bladder instillationwith heparin or hyaluronic acid
were administered on a case-by-case basis.
The study was conducted and completed in July 2011. The
clinical informationwas collected via a chart review and included a
detailed evaluation of history, results of physical examination,
urinalysis, urine cytology, and 48-hour frequencyevolume chart
(FVC) before treatment. Numbers of frequency, nocturia, and
functional bladder capacity were measured from the FVC. The
O’LearyeSant ICSI and ICPI were used to assess the treatment
outcomes. IC symptom and problem severities before and after
treatment were compared. In addition, the Global Response
Assessment Questionnaire was used to evaluate the overall treat-
ment perception.
Statistical analysis was performed by Student’s t test for com-
parisons between the two groups. A probability p < 0.05 was
considered statistically signiﬁcant.
3. Results
During the study period, a total of 73 patients were diagnosed
with IC based on hydrodistention in NCKUH, and 19 patients were
excluded due to incomplete clinical data. Fifty-four patients were
enrolled in this study and the basic clinical informationwas showed
in Table 1. In the study group, 41 patients were female, which gave a
female-to-male ratio of 3.15:1. Average daytime frequency and
nocturia were 13.43 and 3.74 times per day. Mean functional
bladder capacity was 228.1 mL. Combination treatments after
hydrodistention were needed in 98.1% patients (Table 2). Oralpentosan polysulfate (Elmiron 100 mg tid), bladder instillation of
heparin (25,000 units in 30 mL of normal saline), and bladder
instillation of hyaluronic acid (Cystistat 50 mL) were given in 81.5%,
59.3%, and 46.3% patients, respectively. More than one form of
combination treatment modalities were needed in the majority of
patients.
The immediate effect of the 10-minute therapeutic hydro-
distention on bladder capacity is shown in Table 3. Average bladder
capacity at the start of the 10-minute hydrodistention was 422 mL,
which gradually increased by 120.9 mL during the course of ther-
apeutic hydrodistention. No major adverse event such as bladder
rupture occurred. Mild gross hematuria was noted in almost all
patients and they generally recovered within 1 day.
Questionnaire information was obtained from 38 patients. The
average O’LearyeSant ICSI and ICPI scores before treatment were
16.95 and 14.29, respectively. After treatments, both scores were
signiﬁcantly reduced by 24% and 15.5%, respectively (Table 4). In
contrast, 31 patients reported slight or moderate improvements in
Global Response Assessment scores, giving an overall positive
perception rate of 81.6% for long-term treatments (Fig. 1).4. Discussion
IC/PBS is a chronic, debilitating disease mainly affecting women,
while there are reports that the disease affects men and children as
well. Characteristic clinical presentations are urinary urgency and
frequency as well as chronic bladder pain but without any evidence
of bacterial infection. Many patients with IC/PBS have a very poor
quality of life for many years. However, IC is an enigmatic disorder
surrounded by controversies. The etiology is unknown, the patho-
physiology remains uncertain, and the efﬁcacy of treatment regi-
mens is questionable.5 One current issue of debate concerning IC is
the need of diagnostic hydrodistention. In the early 20th century, it
was considered mandatory to see the typical Hunner’s ulcers for
diagnosing IC. Although urologists are no longer seeking Hunner’s
ulcers, petechial hemorrhages or glomerulations in the bladder
after hydrodistention have become the hallmark of diagnosis.
However, evidence has cast doubts on the speciﬁcity of glomer-
ulations in the diagnosis of IC. Waxman et al assessed 20 asymp-
tomatic women undergoing tubal ligation and showed similar
hydrodistention ﬁndings as in patients with IC.6 In the NIDDK
Fig. 1. The seven-point scale is as follows: 3 ¼ markedly worse; 2 ¼ moderately
worse; 1 ¼ slightly worse; 0 ¼ no change; 1 ¼ slightly improved; 2 ¼ moderately
improved; and 3 ¼ markedly improved.
Table 3
The effect of hydrodistention on bladder capacity (n ¼ 54).
Bladder capacity (mL) Mean Median SD Range
Before hydrodistention 422.0 425.0 197.5 60e950
After hydrodistention 542.9* 560.0 220.1 60e1100
*p ¼ 0.0033.
Mean difference ¼ 120.8  40.2 mL.
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diagnosis.4 However, adherence to the NIDDK criteria for clinical
diagnosis of IC is too restrictive and would exclude the majority of
clinical IC patients. In Taiwan, in contrast, cystoscopy with hydro-
distention is usually used for the diagnosis of IC because of the
regulations set by the Bureau of National Health Insurance.
Therapeutically, hydrodistention has been recommended by all
current clinical guidelines as a treatment modality for IC/PBS.
However, the method for hydrodistention has not been standard-
ized.7 Bladder rupture may occur during hydrodistention.8e10
Bladder necrosis due to prolonged distension was also reported.11
In our method, the bladder was inﬂated with normal saline under
a hydrostatic pressure of 80 cmH2O with continuous cystoscopic
monitoring for no more than 10 minutes. During the procedure, if
ﬂuid leakage occurred from the urethra around the cystoscope, no
attempt was made to stop the leak. In addition, we found spinal
anesthesia to be safer than general anesthesia because it could
reduce the risk of inadvertent patient body movement, which oc-
casionally occurred in unconscious patients under shallow general
anesthesia. In our hands, no major complications were recorded
over the years.
In previous studies, hydrodistention of the bladder was reported
to show immediate beneﬁt in relieving the pain and frequency of
voiding in these patients, but its effect gradually decreases. In IC
patients with voiding volumes <200 mL, Aihara et al reported a
median instilled saline volume of 450 mL (250e580 mL) during
hydrodistention; the therapeutic effect was maintained in 71%
of the patients at 1 month with a median duration lasting for
20 weeks.12 In the present study, the bladder capacity under
anesthesia (422.0  197.5 mL) was signiﬁcantly larger than the
functional bladder capacity recorded from urinary diary
(228.1  116.5 mL). The 10-minute therapeutic hydrodistention
could further increase the bladder capacity to 542.9 220.1mL, i.e.,
a 28.6% increment. However, how much of this effect was trans-
lated into long-term therapeutic beneﬁt is questionable. Actually,
only one of our patients received hydrodistention as a single
treatment. The majority of patients still needed other treatments.
The beneﬁts of combination treatments over hydrodistention alone
have been demonstrated by previous studies. Ham et al reported
that intravesical instillation therapy plus hydrodistentionwas more
effective in relieving pain.13 Shao Y et al reported that intravesical
hyaluronic acid and heparin might maintain the effect of hydro-
distention in patients with IC whose functional bladder capacity is
less than 200 mL.14Table 4
The O’LearyeSant Interstitial Cystitis Symptom Index (ICSI) and Problem Index (ICPI)
before and after treatment (n ¼ 38).
Mean Median SD Range
ICSI Before treatment 16.95 18.00 2.959 10e20
After treatment 12.89* 14.00 4.643 4e20
ICPI Before treatment 14.29 15.00 2.514 8e16
After treatment 12.08** 12.50 3.388 4e16
*p < 0.001.
**p ¼ 0.0018.The treatment for patients with IC/PBS is a tough challenge.
Because of the lack of single effective treatment for IC, multiple
treatment modalities are available and combination therapy is
usually required to obtain the best therapeutic outcomes. The pa-
tient must understand that IC is chronic in nature and the primary
goals of therapy are symptom reduction and improvement of
quality of life; cure or complete remission may not be attained.
Current treatment options for IC are dietary control, bladder
retraining, oral medication, intravesical therapy, hydrodistention,
neuromodulation, surgical intervention, and psychological sup-
port.5 In this long-term follow-up series, patients reported only a
moderate improvement (24%) in symptoms and improvement in
problems (15.5%). Understandably, the placebo effect could play a
signiﬁcant role in the treatment of lower urinary tract symptoms,
yielding 32e65% reduction in urinary incontinence and 9e34%
reduction in symptom scores.15 Therefore, the placebo was likely
to be partially responsible for the improvements in our patients. In
contrast, up to 81.6% of the patients graded themselves as either
slightly or moderately improved in the Global Response Assess-
ment Questionnaire. This high percentage of positive perception
was probably not due to the effectiveness of treatment alone, but by
the relentless psychological and emotional supports that the pa-
tients got from their physicians and nurses. The fact that no patient
in this series graded themselves as “markedly improved” suggests
that we had not cured anyone of them. Yet for doctors servicing IC/
PBS patients, we always uphold the belief “We seldom cure, we
always care.” Furthermore, we will also look forward to the
development of new IC treatments such as botulinum toxin or
liposome therapy.16
There are several major limitations in this study: (1) This was a
retrospective study, and the patients did not follow a standard
treatment protocol; (2) there were no control groups for evaluation
of treatment efﬁcacy; and (3) the number of patients in the series
was only moderate. In the future, more meaningful long-term IC
treatment results should be obtained from randomized controlled
studies with larger patient samples.
5. Conclusion
Long-term continual treatments for IC/PBS are appreciated by
most patients even though combinations of modalities are required
and the improvements in symptoms and problems are only
moderate.
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